Frazier Life Sciences Management, L.P. Arcutis Biotherapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 8,785,284 shares of ARQT stock, worth $126 Million. This represents 8.65% of its overall portfolio holdings.
Number of Shares
8,785,284
Previous 8,785,284
-0.0%
Holding current value
$126 Million
Previous $122 Million
12.27%
% of portfolio
8.65%
Previous 7.34%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
251Shares Held
126MCall Options Held
605KPut Options Held
170K-
Suvretta Capital Management, LLC New York, NY11.4MShares$164 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$163 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$157 Million4.91% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$124 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$97.8 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $863M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...